Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 49

1.

Plasma clearance of RAS mutation under therapeutic pressure is a rare event in metastatic colorectal cancer.

Moati E, Blons H, Taly V, Garlan F, Wang-Renault SF, Pietrasz D, Didelot A, Garrigou S, Saint A, Pernot S, Taieb J, Laurent-Puig P, Zaanan A.

Int J Cancer. 2019 Aug 31. doi: 10.1002/ijc.32657. [Epub ahead of print]

PMID:
31472013
2.

How apoptosis and epithelial-to-mesenchymal transition are nested in EGFR inhibitors resistance in lung cancer.

Garinet S, Didelot A, Garelli E, Pallier K, Blons H, Legras A.

J Thorac Dis. 2019 Jan;11(1):47-49. doi: 10.21037/jtd.2018.12.117. No abstract available.

3.

Clinical and molecular characteristics of unicentric mediastinal Castleman disease.

Legras A, Tallet A, Didelot A, Cazes A, Danel C, Hin A, Borie R, Crestani B, Castier Y, Bagan P, Le Pimpec-Barthes F, Riquet M, Blons H, Mordant P.

J Thorac Dis. 2018 Apr;10(4):2079-2088. doi: 10.21037/jtd.2018.03.159.

4.

Role of circulating tumor DNA in the management of patients with colorectal cancer.

Moati E, Taly V, Didelot A, Perkins G, Blons H, Taieb J, Laurent-Puig P, Zaanan A.

Clin Res Hepatol Gastroenterol. 2018 Oct;42(5):396-402. doi: 10.1016/j.clinre.2018.03.002. Epub 2018 Apr 5. Review.

PMID:
29627453
5.

BIABooster: Online DNA Concentration and Size Profiling with a Limit of Detection of 10 fg/μL and Application to High-Sensitivity Characterization of Circulating Cell-Free DNA.

Andriamanampisoa CL, Bancaud A, Boutonnet-Rodat A, Didelot A, Fabre J, Fina F, Garlan F, Garrigou S, Gaudy C, Ginot F, Henaff D, Laurent-Puig P, Morin A, Picot V, Saias L, Taly V, Tomasini P, Zaanan A.

Anal Chem. 2018 Mar 20;90(6):3766-3774. doi: 10.1021/acs.analchem.7b04034. Epub 2018 Mar 9.

PMID:
29498256
6.

Epithelial-to-Mesenchymal Transition and MicroRNAs in Lung Cancer.

Legras A, Pécuchet N, Imbeaud S, Pallier K, Didelot A, Roussel H, Gibault L, Fabre E, Le Pimpec-Barthes F, Laurent-Puig P, Blons H.

Cancers (Basel). 2017 Aug 3;9(8). pii: E101. doi: 10.3390/cancers9080101. Review.

7.

Early Evaluation of Circulating Tumor DNA as Marker of Therapeutic Efficacy in Metastatic Colorectal Cancer Patients (PLACOL Study).

Garlan F, Laurent-Puig P, Sefrioui D, Siauve N, Didelot A, Sarafan-Vasseur N, Michel P, Perkins G, Mulot C, Blons H, Taieb J, Di Fiore F, Taly V, Zaanan A.

Clin Cancer Res. 2017 Sep 15;23(18):5416-5425. doi: 10.1158/1078-0432.CCR-16-3155. Epub 2017 Jun 2.

8.

Base-Position Error Rate Analysis of Next-Generation Sequencing Applied to Circulating Tumor DNA in Non-Small Cell Lung Cancer: A Prospective Study.

Pécuchet N, Zonta E, Didelot A, Combe P, Thibault C, Gibault L, Lours C, Rozenholc Y, Taly V, Laurent-Puig P, Blons H, Fabre E.

PLoS Med. 2016 Dec 27;13(12):e1002199. doi: 10.1371/journal.pmed.1002199. eCollection 2016 Dec.

9.

Plasma Circulating Tumor DNA in Pancreatic Cancer Patients Is a Prognostic Marker.

Pietrasz D, Pécuchet N, Garlan F, Didelot A, Dubreuil O, Doat S, Imbert-Bismut F, Karoui M, Vaillant JC, Taly V, Laurent-Puig P, Bachet JB.

Clin Cancer Res. 2017 Jan 1;23(1):116-123. doi: 10.1158/1078-0432.CCR-16-0806. Epub 2016 Dec 19.

10.

Analysis of Base-Position Error Rate of Next-Generation Sequencing to Detect Tumor Mutations in Circulating DNA.

Pécuchet N, Rozenholc Y, Zonta E, Pietrasz D, Didelot A, Combe P, Gibault L, Bachet JB, Taly V, Fabre E, Blons H, Laurent-Puig P.

Clin Chem. 2016 Nov;62(11):1492-1503. Epub 2016 Sep 13.

11.

Multiplex Detection of Rare Mutations by Picoliter Droplet Based Digital PCR: Sensitivity and Specificity Considerations.

Zonta E, Garlan F, Pécuchet N, Perez-Toralla K, Caen O, Milbury C, Didelot A, Fabre E, Blons H, Laurent-Puig P, Taly V.

PLoS One. 2016 Jul 14;11(7):e0159094. doi: 10.1371/journal.pone.0159094. eCollection 2016.

12.

A Study of Hypermethylated Circulating Tumor DNA as a Universal Colorectal Cancer Biomarker.

Garrigou S, Perkins G, Garlan F, Normand C, Didelot A, Le Corre D, Peyvandi S, Mulot C, Niarra R, Aucouturier P, Chatellier G, Nizard P, Perez-Toralla K, Zonta E, Charpy C, Pujals A, Barau C, Bouché O, Emile JF, Pezet D, Bibeau F, Hutchison JB, Link DR, Zaanan A, Laurent-Puig P, Sobhani I, Taly V.

Clin Chem. 2016 Aug;62(8):1129-39. doi: 10.1373/clinchem.2015.253609. Epub 2016 Jun 1.

13.

[Assessing and making safe the medicine use pathway in paediatrics].

Didelot N, Guerrier C, Didelot A, Fritsch S, Pelte JP, Socha M, Javelot H.

Soins Pediatr Pueric. 2016 May-Jun;(290):35-40. doi: 10.1016/j.spp.2016.03.012. French.

PMID:
27177486
14.

Different prognostic impact of STK11 mutations in non-squamous non-small-cell lung cancer.

Pécuchet N, Laurent-Puig P, Mansuet-Lupo A, Legras A, Alifano M, Pallier K, Didelot A, Gibault L, Danel C, Just PA, Riquet M, Le Pimpec-Barthes F, Damotte D, Fabre E, Blons H.

Oncotarget. 2017 Apr 4;8(14):23831-23840. doi: 10.18632/oncotarget.6379.

15.

Sleep Management Strategy and Performance in an Extreme Mountain Ultra-marathon.

Poussel M, Laroppe J, Hurdiel R, Girard J, Poletti L, Thil C, Didelot A, Chenuel B.

Res Sports Med. 2015;23(3):330-6. doi: 10.1080/15438627.2015.1040916. Epub 2015 May 28.

PMID:
26020095
16.

[Severe PERM syndrom mimicking tetanus].

Wallet F, Didelot A, Delannoy B, Leray V, Guerin C.

Ann Fr Anesth Reanim. 2014 Sep-Oct;33(9-10):530-2. doi: 10.1016/j.annfar.2014.06.008. Epub 2014 Aug 29. French.

PMID:
25168299
17.

[Methandienone misuse: interest of medical anti-doping units].

Poussel M, Renaud P, Gambier N, Didelot A, Favre A, Chenuel B.

Therapie. 2014 May-Jun;69(3):249-50. doi: 10.2515/therapie/2014023. Epub 2014 Jun 18. French.

PMID:
24934822
18.

ERBB2 gene as a potential therapeutic target in small bowel adenocarcinoma.

Laforest A, Aparicio T, Zaanan A, Silva FP, Didelot A, Desbeaux A, Le Corre D, Benhaim L, Pallier K, Aust D, Pistorius S, Blons H, Svrcek M, Laurent-Puig P.

Eur J Cancer. 2014 Jul;50(10):1740-1746. doi: 10.1016/j.ejca.2014.04.007. Epub 2014 May 2.

PMID:
24797764
19.

Hsa-miR-31-3p expression is linked to progression-free survival in patients with KRAS wild-type metastatic colorectal cancer treated with anti-EGFR therapy.

Manceau G, Imbeaud S, Thiébaut R, Liébaert F, Fontaine K, Rousseau F, Génin B, Le Corre D, Didelot A, Vincent M, Bachet JB, Chibaudel B, Bouché O, Landi B, Bibeau F, Leroy K, Penault-Llorca F, Van Laethem JL, Demetter P, Tejpar S, Rossi S, Mosakhani N, Osterlund P, Ristamäki R, Sarhadi V, Knuutila S, Boige V, André T, Laurent-Puig P.

Clin Cancer Res. 2014 Jun 15;20(12):3338-47. doi: 10.1158/1078-0432.CCR-13-2750. Epub 2014 Apr 25.

20.

The new histologic classification of lung primary adenocarcinoma subtypes is a reliable prognostic marker and identifies tumors with different mutation status: the experience of a French cohort.

Mansuet-Lupo A, Bobbio A, Blons H, Becht E, Ouakrim H, Didelot A, Charpentier MC, Bain S, Marmey B, Bonjour P, Biton J, Cremer I, Dieu-Nosjean MC, Sautès-Fridman C, Régnard JF, Laurent-Puig P, Alifano M, Damotte D.

Chest. 2014 Sep;146(3):633-643. doi: 10.1378/chest.13-2499.

PMID:
24676429
21.

Paraneoplastic disorders of the central and peripheral nervous systems.

Didelot A, Honnorat J.

Handb Clin Neurol. 2014;121:1159-79. doi: 10.1016/B978-0-7020-4088-7.00078-X. Review.

PMID:
24365410
22.

Autoimmune N-methyl-D-aspartate receptor encephalitis is a differential diagnosis of infectious encephalitis.

Thomas L, Mailles A, Desestret V, Ducray F, Mathias E, Rogemond V, Didelot A, Marignier S, Stahl JP, Honnorat J; Steering Committee and Investigators Group.

J Infect. 2014 May;68(5):419-25. doi: 10.1016/j.jinf.2013.12.001. Epub 2013 Dec 17.

PMID:
24355654
23.

Anti-NMDA receptor encephalitis mimicking a primary psychiatric disorder in a 13-year-old girl.

Ben Achour N, Ben Youssef-Turki I, Messelmani M, Kraoua I, Yaacoubi J, Klaa H, Rouissi A, Benrhouma H, Ben Ahmed M, Didelot A, Ducray F, Gouider-Khouja N.

Turk Psikiyatri Derg. 2013 Summer;24(2):145-7. English, Turkish. No abstract available.

PMID:
23905172
24.

Autoimmune limbic encephalopathy and anti-Hu antibodies in children without cancer.

Honnorat J, Didelot A, Karantoni E, Ville D, Ducray F, Lambert L, Deiva K, Garcia M, Pichit P, Cavillon G, Rogemond V, DeLattre JY, Tardieu M.

Neurology. 2013 Jun 11;80(24):2226-32. doi: 10.1212/WNL.0b013e318296e9c3. Epub 2013 May 8.

PMID:
23658383
25.

Multiplex picoliter-droplet digital PCR for quantitative assessment of DNA integrity in clinical samples.

Didelot A, Kotsopoulos SK, Lupo A, Pekin D, Li X, Atochin I, Srinivasan P, Zhong Q, Olson J, Link DR, Laurent-Puig P, Blons H, Hutchison JB, Taly V.

Clin Chem. 2013 May;59(5):815-23. doi: 10.1373/clinchem.2012.193409. Epub 2013 Feb 12.

26.

Recurrent inactivating mutations of ARID2 in non-small cell lung carcinoma.

Manceau G, Letouzé E, Guichard C, Didelot A, Cazes A, Corté H, Fabre E, Pallier K, Imbeaud S, Le Pimpec-Barthes F, Zucman-Rossi J, Laurent-Puig P, Blons H.

Int J Cancer. 2013 May 1;132(9):2217-21. doi: 10.1002/ijc.27900. Epub 2012 Nov 20.

27.

Disrupted surface cross-talk between NMDA and Ephrin-B2 receptors in anti-NMDA encephalitis.

Mikasova L, De Rossi P, Bouchet D, Georges F, Rogemond V, Didelot A, Meissirel C, Honnorat J, Groc L.

Brain. 2012 May;135(Pt 5):1606-21. doi: 10.1093/brain/aws092.

PMID:
22544902
28.

Limbic encephalitis and type 1 diabetes with glutamic acid decarboxylase 65 (GAD65) autoimmunity: improvement with high-dose intravenous immunoglobulin therapy.

Lopez-Sublet M, Bihan H, Reach G, Dupont S, Didelot A, Mourad JJ, Krivitzky A, Dhote R.

Diabetes Metab. 2012 Jun;38(3):273-5. doi: 10.1016/j.diabet.2012.02.005. Epub 2012 Mar 29.

PMID:
22463975
29.

Competitive allele specific TaqMan PCR for KRAS, BRAF and EGFR mutation detection in clinical formalin fixed paraffin embedded samples.

Didelot A, Le Corre D, Luscan A, Cazes A, Pallier K, Emile JF, Laurent-Puig P, Blons H.

Exp Mol Pathol. 2012 Jun;92(3):275-80. doi: 10.1016/j.yexmp.2012.03.001. Epub 2012 Mar 7.

PMID:
22426079
30.

Anti-N-methyl-D-aspartate receptor encephalitis with acute disseminated encephalomyelitis-like MRI features.

Lekoubou A, Viaccoz A, Didelot A, Anastasi A, Marignier R, Ducray F, Rogemond V, Honnorat J.

Eur J Neurol. 2012 Feb;19(2):e16-7. doi: 10.1111/j.1468-1331.2011.03617.x. Epub 2011 Dec 19. No abstract available.

PMID:
22182357
31.

Anti-N-methyl-D-aspartate receptor encephalitis complicating ovarian teratomas: a case report.

Naoura I, Didelot A, Walker F, Luton D, Koskas M.

Am J Obstet Gynecol. 2011 Oct;205(4):e6-8. doi: 10.1016/j.ajog.2011.05.008. Epub 2011 May 10.

PMID:
21704961
32.

Subcontinuous epileptiform activity after failed hippocampal radiosurgery.

Rheims S, Didelot A, Guenot M, Regis J, Ryvlin P.

Epilepsia. 2011 Aug;52(8):1425-9. doi: 10.1111/j.1528-1167.2011.03123.x. Epub 2011 Jun 10.

33.

Malignant catatonia due to anti-NMDA-receptor encephalitis in a 17-year-old girl: case report.

Consoli A, Ronen K, An-Gourfinkel I, Barbeau M, Marra D, Costedoat-Chalumeau N, Montefiore D, Maksud P, Bonnot O, Didelot A, Amoura Z, Vidailhet M, Cohen D.

Child Adolesc Psychiatry Ment Health. 2011 May 13;5(1):15. doi: 10.1186/1753-2000-5-15.

34.

In vivo effects of antibodies from patients with anti-NMDA receptor encephalitis: further evidence of synaptic glutamatergic dysfunction.

Manto M, Dalmau J, Didelot A, Rogemond V, Honnorat J.

Orphanet J Rare Dis. 2010 Nov 26;5:31. doi: 10.1186/1750-1172-5-31.

35.

Voxel-based analysis of asymmetry index maps increases the specificity of 18F-MPPF PET abnormalities for localizing the epileptogenic zone in temporal lobe epilepsies.

Didelot A, Mauguière F, Redouté J, Bouvard S, Lothe A, Reilhac A, Hammers A, Costes N, Ryvlin P.

J Nucl Med. 2010 Nov;51(11):1732-9. doi: 10.2967/jnumed.109.070938.

36.

[Paraneoplastic neurological syndromes].

Didelot A, Honnorat J.

Rev Med Interne. 2011 Oct;32(10):605-11. doi: 10.1016/j.revmed.2010.09.007. Epub 2010 Oct 30. Review. French.

PMID:
21036427
37.

Afferent facilitation of corticomotor responses is increased by IgGs of patients with NMDA-receptor antibodies.

Manto M, Dalmau J, Didelot A, Rogemond V, Honnorat J.

J Neurol. 2011 Jan;258(1):27-33. doi: 10.1007/s00415-010-5674-5. Epub 2010 Jul 24.

38.

HLA-DQ2+ individuals are susceptible to Hu-Ab associated paraneoplastic neurological syndromes.

de Graaf MT, de Beukelaar JW, Haasnoot GW, Levering WH, Rogemond V, Didelot A, Honnorat J, Gratama JW, Smitt PA.

J Neuroimmunol. 2010 Sep 14;226(1-2):147-9. doi: 10.1016/j.jneuroim.2010.05.035. Epub 2010 Jun 12.

PMID:
20547426
39.

Facial pain as first manifestation of anti-Hu paraneoplastic syndrome.

Demarquay G, Didelot A, Rogemond V, Ryvlin P, Gouttard M, Garassus P, Mauguière F, Honnorat J.

J Headache Pain. 2010 Aug;11(4):355-7. doi: 10.1007/s10194-010-0212-5. Epub 2010 Apr 13.

40.

Neurosarcoidosis with diencephalitis and anti-Ma2 antibodies.

Desestret V, Didelot A, Meyronet D, Bruyas A, Jouvet A, Honnorat J.

Neurology. 2010 Mar 2;74(9):772-4. doi: 10.1212/WNL.0b013e3181d25b80. No abstract available.

PMID:
20194918
41.

Initial neuro-ophthalmological manifestations in Churg-Strauss syndrome.

Vallet AE, Didelot A, Guebre-Egziabher F, Bernard M, Mauguière F.

BMJ Case Rep. 2010 Oct 12;2010. pii: bcr0820092219. doi: 10.1136/bcr.08.2009.2219.

42.

Expanding spectrum of encephalitis with NMDA receptor antibodies in young children.

Lebas A, Husson B, Didelot A, Honnorat J, Tardieu M.

J Child Neurol. 2010 Jun;25(6):742-5. doi: 10.1177/0883073809343319. Epub 2009 Oct 15.

PMID:
19833974
43.

Update on paraneoplastic neurological syndromes.

Didelot A, Honnorat J.

Curr Opin Oncol. 2009 Nov;21(6):566-72. doi: 10.1097/CCO.0b013e3283306647. Review.

PMID:
19620862
44.

PET imaging of brain 5-HT1A receptors in the preoperative evaluation of temporal lobe epilepsy.

Didelot A, Ryvlin P, Lothe A, Merlet I, Hammers A, Mauguière F.

Brain. 2008 Oct;131(Pt 10):2751-64. doi: 10.1093/brain/awn220. Epub 2008 Sep 12.

PMID:
18790822
45.

Comorbidity between temporal lobe epilepsy and depression: a [18F]MPPF PET study.

Lothe A, Didelot A, Hammers A, Costes N, Saoud M, Gilliam F, Ryvlin P.

Brain. 2008 Oct;131(Pt 10):2765-82. doi: 10.1093/brain/awn194. Epub 2008 Sep 2.

46.

[Syndrome of headache with neurologic deficits and CSF lymphocytosis].

Guilloton L, Didelot A, Gouillou A, Felten D, Drouet A.

Rev Med Interne. 2008 May;29(5):397-400. doi: 10.1016/j.revmed.2007.11.008. Epub 2008 Jan 3. French.

PMID:
18180076
47.

Concomitant bone marrow metastasis of a glioblastoma multiforme revealed at the diagnosis.

Didelot A, Taillandier L, Grignon Y, Vespignani H, Beauchesne P.

Acta Neurochir (Wien). 2006 Sep;148(9):997-1000. Epub 2006 Aug 25.

PMID:
16932995
48.

[MRI findings in a case of prolonged status epilepticus].

Didelot A, Kremer S, Schmitt E, Maillard L, Gibot S, Cravoisi A, Vespignani H, Bracard S, Picard L.

J Neuroradiol. 2006 Apr;33(2):121-5. French.

PMID:
16733426
49.

[Systemic metastasis at the time of diagnosis of a glioblastoma].

Montagne K, Marie B, Cahn V, Hennequin V, Didelot A, N'Seir R, Beauchesne P, Grignon Y.

Ann Pathol. 2004 Jun;24(3):268-70. French.

PMID:
15480263

Supplemental Content

Loading ...
Support Center